Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) based on ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Waller, John, Mitra, Debanjali, Mycock, Katie, Taylor-Stokes, Gavin, Milligan, Gary, Zhan, Lin, Iyer, Shrividya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550052/
https://www.ncbi.nlm.nih.gov/pubmed/31050919
http://dx.doi.org/10.1200/JGO.18.00239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550052/
https://www.ncbi.nlm.nih.gov/pubmed/31050919
http://dx.doi.org/10.1200/JGO.18.00239

Ejemplares similares